DB08890

GPTKB entity

Statements (44)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 2010
gptkbp:ATCCode B01AE07
gptkbp:bioavailability 6.5%
gptkbp:brand gptkb:Pradaxa
gptkbp:CASNumber 211914-51-1
gptkbp:contraindication active pathological bleeding
mechanical prosthetic heart valves
gptkbp:developedBy gptkb:Boehringer_Ingelheim
gptkbp:drugClass gptkb:anticoagulant
antithrombotic agent
gptkbp:eliminationHalfLife 12-17 hours
gptkbp:excretion gptkb:kidney
gptkbp:hasBoxedWarning increased risk of thrombotic events after premature discontinuation
risk of spinal/epidural hematoma
gptkbp:hasInChIKey XXRSQQJQSRQVQN-UHFFFAOYSA-N
gptkbp:hasMolecularFormula C34H41N7O5
gptkbp:hasSMILES CCOC(=O)C(=NOC(=O)C1=CC=CC=C1)N(C)C2=NC3=CC=CC=C3N2C4=CC=CC=C4
gptkbp:hasUNII 2ZC8352B2L
https://www.w3.org/2000/01/rdf-schema#label DB08890
gptkbp:indication treatment and prevention of deep vein thrombosis
treatment and prevention of pulmonary embolism
prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
gptkbp:legalStatus prescription only
patented
gptkbp:mechanismOfAction direct thrombin inhibitor
gptkbp:metabolism liver
gptkbp:molecularWeight 627.74
gptkbp:name gptkb:Dabigatran
gptkbp:pregnancyCategory C (US)
gptkbp:proteinBinding 35%
gptkbp:PubChem_CID gptkb:CHEMBL1201197
gptkb:DB08890
148124
D08167
gptkbp:routeOfAdministration oral
gptkbp:sideEffect bleeding
gastrointestinal upset
gptkbp:status true
gptkbp:synonym gptkb:Dabigatran_etexilate
gptkb:Dabigatran_etexilate_mesylate
gptkbp:target gptkb:thrombin
gptkbp:bfsParent gptkb:linaclotide
gptkbp:bfsLayer 6